Get Details

Development Pipeline

We are engineering a broad pipeline based on clinically validated drug targets that are designed to create a high therapeutic index by maximizing potency while minimizing toxicity.

Janux’s initial development programs are designed to activate T cells within the tumor microenvironment. The company leverages its proprietary tumor activated T cell engager (TRACTr) and its tumor activated immunomodulator (TRACIr) platforms to develop bispecific molecules that once activated are precision engineered to bind to specific tumor antigens and to T cells, thereby focusing T cells to attack the cancer while limiting toxicity elsewhere in the body. Activation of the TRACTrs and TRACIrs within the tumor microenvironment limits toxicity elsewhere in the body.
Program
Targets
Indications
  • Discovery
  • IND-Enabling
  • Ph 1
  • Ph 2
  • Ph 3

WHOLLY OWNED TRACTr PROGRAMS

PSMA x CD3
mCRPC
  • Phase 1
EGFR x CD3
CRC, NSCLC, SCCHN, RCC
  • Phase 1
TxCD3
Undisclosed
  • Discovery

WHOLLY OWNED TRACIr PROGRAMS

TxCD28
Undisclosed
  • Discovery

WHOLLY OWNED TRACTr PROGRAMS

Targets
PSMA x CD3
Init. Indications
mCRPC
Progress
Phase 1
Targets
EGFR x CD3
Init. Indications
CRC, NSCLC, SCCHN, RCC
Progress
Phase 1
Targets
TxCD3
Init. Indications
Undisclosed
Progress
Discovery

WHOLLY OWNED TRACIr PROGRAMS

Targets
TxCD28
Init. Indications
Undisclosed
Progress
Discovery

Learn about our clinical trial programs.